• The global precision medicine market is expected to reach revenues of over $216.75 billion by 2028, propelled by a growing interest in personalized approaches to disease treatments and the application of new technologies
• Precision Therapeutics and its three wholly owned subdivisions are advancing the company’s goals of applying artificial intelligence to precision medicine and drug research to improve patient care
• The company’s Helomics subdivision analyzes disease data, particularly in targeting cancer therapies, and develops applicable technologies; the TumorGenesis division develops tumor-fighting tactics, and the Skyline Medical division markets a device that facilitates biological fluid collection in the medical arena
• Helomics was recently selected as the lab of choice for a grant-funded effort to develop test kits for screening prescription drug contaminants

Personalized medicine technology developer Precision Therapeutics Inc. (NASDAQ: AIPT) has added a new biomedical research partnership to its portfolio, furthering its mission to apply artificial intelligence to precision medicine and drug discovery in an effort to improve the quality of patient care.

The innovative use of applied science in building artificial intelligence applications for medical advancement led Precision Therapeutics’ Helomics division to be selected as the preferred laboratory for the recently funded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) grant to develop test kits for screening certain prescription drug contaminants.

The Accukit product will be used to test for microbial and viral contamination of biopharmaceuticals, with the goal of improving biosafety testing for biopharmaceutical products, according to the company’s statement about the agreement (http://ibn.fm/k1clX). AccuGenomics Inc., Celgene, Merck and North Carolina State University are also partnering in the enterprise.

Helomics will work on a highly sensitive Next Generation Sequencing-based platform to streamline screening biopharmaceuticals for the contaminants. The Accukit is expected to be able to detect 22 known but unintended viruses and bacteria at sensitivity levels required to pass strict quality control standards.

“The opportunity to contribute to innovative approaches to drug development is an important part of our business,” Helomics President Gerald Vardzel stated in a news release. “Our state of the art and highly recognized CLIA-certified lab in Pittsburgh contributes to our remaining at the cutting edge of innovation with leading edge partners that utilize our boutique contract research services.”

Helomics is one of three wholly owned Precision Therapeutics subsidiaries, the others being TumorGenesis and Skyline Medical. TumorGenesis is developing a new rapid approach to growing tumors in the laboratory to trick cancer cells into thinking they are still growing inside a patient, with the ultimate goal being to obtain information about the cells that can then be used to develop patient-specific treatment options. Skyline Medical markets the company’s patented and FDA-cleared STREAMWAY System for the automated collection, measurement and disposal of waste fluids within medical facilities, such as blood and surgical irrigation fluid.

Working together, Precision Therapeutics’ divisions advance its efforts to positively improve the effectiveness of cancer therapy using the power of AI and the company’s rich database of disease particulars gathered from the study of patient tumors to help patients and drive the development of new pharmaceutical therapies.

Precision medicine is a multibillion-dollar market that is gaining stature among populations of all ages, not only because of the therapies’ approach to individualized attention but also because of the growing use of technological advances for personal health care devices that include smart technologies. Precision medicine got a further push when the U.S. government’s Precision Medicine Initiative was introduced in 2015 (http://ibn.fm/QE0M6). Market analysts at BIS Research predict that, between 2018 and 2028, the global precision medicine market could grow from $78.85 billion to over $216.75 billion at a CAGR of 10.64 percent (http://ibn.fm/20FrL).

For more information, visit the company’s website at www.PrecisionTherapeutics.com

• The CFO of CIIX’s CBD Biotechnology Co. Ltd. is scheduled to speak at the microcap conference
• The company official is expected to share exciting new developments related to its hemp product line with current and prospective investors
• The company anticipates exciting opportunities for business growth in the coming months

ChineseInvestors.com Inc. (OTCQB: CIIX) will be an official presenter at the 9th Annual LD Micro Invitational to be held June 4-5 at the Luxe Sunset Boulevard Hotel in Bel-Air, California. Alex Hamilton, chief financial officer of CIIX’s wholly owned foreign enterprise, CBD Biotechnology Co. Ltd., will present a corporate overview at 2:20 p.m. PT on the opening day of the conference.

Hamilton will discuss recent business highlights with regard to the Chinese industrial hemp/CBD business. He will also be available for one-on-one meetings with investors during the conference.

“This conference is a great venue for emerging and rapid-growth companies,” Hamilton said in a news release (http://ibn.fm/LhGa0). “We are very much looking forward to sharing our exciting new developments of our hemp product line with current and prospective investors. We believe there will be some exciting opportunities for our business and growth expansions for our product lines in the coming months, which makes this an exciting time to be out sharing our corporate vision.”

The LD Micro Invitational conference began in 2006 with the purpose of being an independent resource in the microcap space. The June Invitational is scheduled to have 250 corporate participants and is expected to attract more than 1,000 attendees.

CIIX is a diverse company that offers its audience of Chinese-speaking investors real-time market commentary, analysis and education-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• SGSI is a leading provider of telecommunications engineering and infrastructure services and solutions
• The company is ready to meet the growing demand for 5G infrastructure
• SGSI recently announced multimillion-dollar revenue with positive income

Spectrum Global Solutions Inc. (OTCQB: SGSI) is a foremost provider of comprehensive outsourced services and solutions for the deployment and maintenance of next-generation and legacy wireless and wireline telecommunication networks and infrastructure. The company has successfully executed on projects across the United States and globally. Based in Longwood, Florida, Spectrum is professionally registered in 49 states, three U.S. territories (Puerto Rico, the Unites States Virgin Islands and Guam) and six Canadian provinces in support of its clients (http://ibn.fm/UJWDC).

The company provides services directly to carriers, aggregators, utilities, enterprise operations, project management organizations (PMOs) and original equipment manufacturer (OEM) clientele via diverse subsidiaries. These subsidiaries include AW Solutions Inc. and AW Solutions Puerto Rico LLC; ADEX Corporation and ADEX Puerto Rico LLC; Tropical Communications Inc.; and TNS Inc.

AW Solutions provides telecommunications and engineering services, along with cost-effective, scalable and strong solutions for organizations’ technology deployments (http://ibn.fm/i6jt8). ADEX Corporation provides turnkey services and project staffing solutions solely to the telecommunications industry. ADEX provides infrastructure services globally through domestic and international locations (http://ibn.fm/b7r9P).

Subsidiary Tropical Communications is a state-licensed electrical and underground utility contractor headquartered in Miami, Florida. It provides all kinds of communications and infrastructure facility structured wiring services and solutions (http://ibn.fm/l6oQ4). The TNS Inc. subsidiary specializes in the design, installation and maintenance of structured cabling systems using Tier 1 products (Mohawk, Hubbell, Berk-Tek, Ortronics and more). TNS’s Tier 1 testing equipment (Fluke DSX 1800) is used to test and certify every one of its installations (http://ibn.fm/jnx7T).

Spectrum Global Solutions’ services range in scope from a single activity to multiyear, multi-region large-scale turnkey development contracts. The company uses licensed professional engineers, project managers, technicians and general contractors. Through these experts, Spectrum has completed more than 150,000 project activities on wireless, DAS (Distributed Antenna System), wireline and fiber networks throughout the United States.

Spectrum is one of the few engineering and installation firms able to provide all services and bundle products for telcos. The company is focusing on its 5G networks rollout this year and is well-positioned to meet the increasing demand for 5G. The expectation is that the 5G rollout will create three million U.S. jobs and drive more than $500 billion in U.S. GDP growth (http://ibn.fm/0Q0Wx). Spectrum Global Solutions is among the few elite full-service engineering, construction, installation, maintenance and professional services organizations for these next-generation telecommunications networks.

Recently, Spectrum announced that it received new contract awards worth over $3.7 million to support carrier-network upgrades (http://ibn.fm/ZclhV). The company also recently reported financial results for the fiscal period ended March 31, 2019, with revenue of $11,335,732 for Q1 2019 versus $4,327,764 from Q1 2018 (http://ibn.fm/hKLFn).

“Revenue was just over $11.3 million, which reflects consistent growth in our AW Solutions, ADEX and TNS subsidiaries,” Spectrum CEO and President Roger Ponder stated in a news release. “We also reported positive income from operations for the period. This is Spectrum’s first quarter with positive income from operations, which demonstrates continued improvements in the business.”

Spectrum Global Solutions offers a compelling investment opportunity with its ability to provide a full slate of telecommunications and enterprise services. The company has embedded customer relationships that foster repeat customers at minimal customer acquisition costs, and it continues to be a proven operator in the high-growth telecom market.

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to SGSI are available in the company’s newsroom at http://ibn.fm/SGSI

• The company is now able to fulfill inquiries about white labeling its full-spectrum cannabinoids line
• ETST has added markets for CBD products through two distribution agreements
• The company continues to eye product placement in large chain and health food stores, dispensaries, chiropractor offices, athletic clubs and clinics

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, is seeking to gain more market share through its white-label initiative that offers marketers the ability to rebrand its full-spectrum cannabinoids line (http://ibn.fm/frikT).

“I’m excited to share that our sales have consistently increased over 100% every month,” ETST Chairman Nickolas S. Tabraue stated in a news release. “We have also received countless white-labeling inquiries, and thanks to our reliable source and manufacturer, we are now able to fulfill these inquiries and capture even more market share.”

White labeling enables a company to benefit from the branding and distribution channels of other brands (http://ibn.fm/wfJTD) and is a strategy designed to create more loyalty and insular protection for ETST in the competitive cannabis market. ETST has collaborated with its manufacturing partner to launch the white labeling initiative (http://ibn.fm/oJzGf).

This program is expected to help ETST gain market share at a time when the company is also broadening its target markets to include larger chain and health food stores, pharmacies, dispensaries, chiropractor offices, athletic clubs and clinics. ETST has signed agreements with Desert Sun Distribution and Cannabiz to distribute to health care practitioners and pharmacies.

Based in Doral, Florida, ETST offers cannabinoids in the form of softgels, tablets, liquids and other options classified as food-based and permissible in all 50 states in the United States and some 40 countries globally.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• MRMD improved its adjusted EBITDA in Q1 2019 by 76 percent
• The company’s multipronged strategy for growth includes continued consolidation of cannabis operations and the launch of a subsidiary
• MariMed CEO identified the company as a “significant early mover” in the burgeoning CBD health and wellness market

MariMed Inc. (OTCQB: MRMD) recorded a 69 percent jump in revenues to $3,515,815 for the three months ended March 31, 2019, as compared to $2,082,950 for the comparable period of the prior year. The company’s gross profit for the quarter rose 90 percent, to $2,261,025, from $1,194,081 for the same period in 2018. MRMD is actively pursuing additional growth as it moves to expand brand licensing and open more cannabis facilities in several states (http://ibn.fm/yrLJg).

MRMD’s adjusted EBITDA increased 76 percent to $585,000 in Q1 2019, up from $332,000 in the comparable period of the prior year. Reported net loss for the same quarter was $23,211, marking a 99 percent improvement from the $1,895,142 loss reported in the same period of 2018.

MariMed has adopted a multipronged strategy for growth in 2019. That strategy includes continuing consolidation of operations, which is expected to be completed over the next several months, and the launch of MariMed Hemp Inc., a wholly owned subsidiary in the hemp-based CBD market for health and wellness products. Marimed is developing new CBD brands and products that will be distributed to retailers and reps of health and medical businesses.

“We continue to see dynamic growth in our cannabis operations, even as we have become a significant early mover in the burgeoning CBD health and wellness market,” MRMD CEO Bob Fireman stated in a news release (http://ibn.fm/EvN0I). “We are encouraged by our continued strong operating performance, and look forward to realizing the benefits of investments and initiatives undertaken over the last two quarters, which includes the ongoing consolidation of cannabis operations, the opening of additional cannabis facilities in several states, expanding the licensing of our brands and products into additional licensed states, and our multipronged entry into the CBD market.”

MRMD offers a full range of cannabis products, operates dispensaries in six states and is focused on the development of MariMed Hemp. MariMed Hemp owns a significant share of Kentucky-based GenCanna Global Inc., an industrial hemp genetic innovator. MRMD recently converted debt investment (debentures) in GenCanna Global into a significant equity position in that company, which is a leader in vertically integrated hemp cultivation and a producer of Good Manufacturing Practices-compliant CBD products.

For more information, visit the company’s website at www.MariMedAdvisors.com

• Endonovo’s flagship product, SofPulse, is an easy-to-place, non-invasive device delivering pulsed electromagnetic frequencies to enhance post-surgical recovery
• The company’s agreement with Veterans Healthcare Supply Solutions Inc. includes distribution of SofPulse to Veterans Administration facilities and Department of Defense health care facilities
• Treatment with SofPulse allows patients to better manage post-operative pain without the adverse side effects of narcotics and anti-inflammatory medications
• Endonovo holds patents and trademarks for several proprietary technologies and devices

Endonovo Therapeutics Inc. (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver proprietary, patent protected Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. As an innovative biotechnology company, Endonovo is harnessing bioelectricity to restore key electrochemical processes that initiate the anti-inflammatory and growth factor cascades necessary for healing to occur.

The long-term agreement recently signed with Veterans Healthcare Supply Solutions Inc. (“VHSS”) to directly distribute SofPulse devices to Veterans Administration facilities and Department of Defense health care facilities extends beyond traditional distribution methods, Endonovo CEO Alan Collier said in a news release (http://ibn.fm/MHvji).

“The team at VHSS have streamlined and improved the sales, marketing and distribution of medical devices to VA and DoD facilities. VHSS is a true leader in the space and we are thrilled to have the capacity to support their mission,” Collier stated in a news release. “This agreement, which includes direct delivery to all medical facilities, extends beyond traditional distribution and includes access to their 900 Federal Contract Officers as well as their distribution center with a state-of-the-art ERP and WMS Systems.”

Endonovo’s flagship product, SofPulse, is an easy-to-place, non-invasive device delivering pulsed electromagnetic frequencies to enhance post-surgical recovery, and it can be used as a standalone therapy or integrated into any treatment protocol. SofPulse uses targeted microcurrents to transmit gentle pulses to the tissue to help reduce swelling and speed up the natural recovery process.

“VHSS is excited to partner with Endonovo, as our primary goal is providing leading edge products and services to eligible federal government health care constituents,” added Gary Skura, VHSS president and retired Navy pilot with over 30 years of health care distribution experience. “Our new partnership with Endonovo will certainly allow us to further continue our core objectives.”

Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema (swelling) and is CE-marked in the European Economic Area (EEA) for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services (CMS) also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Nabis Holdings discussed the importance of cannabis legislative changes during an inaugural edition of a congressional cannabis forum in Washington, DC
• The company also announced the acquisition of a cannabis extraction and production facility in Washington state
• Through modernization and expansion, the company plans to ramp up the facility’s production capacity to 20,500 kilograms per year

Jade Green, special advisor to Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), participated in the KCSA Strategic Communications’ Inaugural Congressional Cannabis Day Forum that took place in Washington, DC on May 21, 2019. Green attended a panel discussing important legislative changes such as the federal Farm Bill and the impact that these developments have had on the cannabis industry, according to a company press release (http://ibn.fm/FdhPU).

This first-of-its-kind event provided opportunities for engagement in dialogue about cannabis and the related legislative changes occurring in the country, Green said in a news release. “Nabis will continue to be a part of the resounding voices urging congress to modernize federal cannabis laws to more effectively facilitate the growth of America’s small businesses and provide protections for consumers,” she continued.

The aim of the Congressional Cannabis Day Forum was to take a deep look at the current state and the future of the cannabis industry. The forum featured a series of panel discussions that focused on critical issues like capital markets, social justice, veterans’ issues and CBD/hemp, among others.

Nabis Holdings is a Canadian investment company that invests in high quality assets across various industries. Its primary areas of specialization include cryptocurrency, securities, real property and all aspects of the U.S. and international cannabis sectors.

Earlier in May, the company released information about a new key acquisition in the U.S. cannabis sector. On May 13, 2019, Nabis Holdings announced the purchase of several assets from PDT Technologies LLC, including an established cannabis extraction and production facility in Washington State (http://ibn.fm/LWZLx).

A definitive agreement for the purchase has already been signed. In addition to the production facility, Nabis Holdings will be purchasing extraction and production equipment, as well as the exclusive licensing rights throughout Washington for a leading brand of cannabis products called ‘Chong’s Choice’.

The PDT production facility, based in Port Townsend, specializes in high grade cannabis concentrate. Through an investment of approximately $3 million, Nabis plans to expand the facility to include new specialized equipment, two new extraction lines, a lab facility and a clean room.

Following the improvements, the facility’s capacity is expected to reach 20,500 kilograms of cannabis concentrate per year.

Finalizing the agreement with PDT will enable Nabis to expand its footprint and licensing capabilities in Washington state, Nabis CEO Shay Shnet said in a news release. The purchase of new equipment and modification of the existing facility are both in line with the company’s aggressive expansion plan.

Washington state has a relatively mature market with proven metrics. Nabis Holdings will continue evaluating new local opportunities, as well as acquisition possibilities in other limited license states.

For more information, visit the company’s website at www.NabisHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to INNPF are available in the company’s newsroom at http://ibn.fm/INNPF

• Geyser Brands recently commenced upgrades; it anticipates R&D and processing amendments
• The facility expansion is expected to improve the company’s focus on processing quality and consumer satisfaction
• Solace Management Group recently increased its production capacity and invested in new equipment for consumer health care and pet wellness production

Geyser Brands Inc. (TSX.V: GYSR) is a leading Vancouver-based consumer health care company producing some of the world’s most popular cannabis brands and products. The company’s licensed producer (LP), Apothecary Botanicals, has received Health Canada license amendment approval to update its 7,000-square-foot facility located in Port Coquitlam, British Columbia.

This expansion, anticipated to be complete by the end of June 2019, would allow for research and development (R&D) and processing capabilities in anticipation of receiving its licensed amendments. GYSR’s R&D license is pending Health Canada’s approval of the LP facility, though the company’s facility was recently audited by Health Canada and found to be fully compliant. The company hopes to enhance its long-term success through attaining a processing license, which Geyser Brands believes will help it capitalize in the CBD wellness product market that’s predicted to be a multibillion-dollar industry (http://ibn.fm/J7DNm).

The company’s facility expansion is anticipated to include mothering and cloning rooms, along with designated areas for working with approved seed banks. A focus on processing quality will allow Geyser Brands to ensure high-CBD seed strains with consistent cannabinoid profiles, providing a reliable quality experience for consumers via its products.

Additionally, Geyser Brands recently recognized an achievement of its acquisition target, Solace Management Group Inc. GMP-compliant Solace is now in its new manufacturing facility, which is located in Coquitlam, British Columbia.

Solace hosts a dynamic portfolio of both pet and consumer health care goods, and the new facility adds to its focus on processing quality. The 7,500-square-foot construction increases production capacity by up to tenfold (http://ibn.fm/cf5Vg) and allows Solace to “develop and license new products that are either ready for production or are in various stages of development.”

In an effort to partially or fully automate processes, new equipment has also been added to the facility, including an industrial oven, advanced blending and mixing systems, rotary depositing, large-volume kettle blending, a tincture mottling system and vertical-form-fill packaging. Because of these advancements, Solace is expected to be able to meet growing market demand for its products.

In 2018, the Global Wellness Institute estimated that the global wellness economy was a $4.2 trillion market that has shown growth in recent years (http://ibn.fm/kOaHX). The teams at Geyser Brands and Solace realize the industry’s demand for product innovation and consumer satisfaction. Together, they aim to provide healthy and relevant products to a burgeoning consumer base.

“The new production facility is definitely a milestone for Solace,” Geyser Brands CEO Andreas Thatcher stated in a news release (http://ibn.fm/Mnye5). “The acquisition of Solace will provide us with a great head start as we seek to establish ourselves as a leading provider of health-focused hemp and CBD products. We have some new amazing products in the queue and being able to fulfill demand is key.”

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• Long-term agreement signed with Veterans Healthcare Supply Solutions Inc. to directly distribute SofPulse devices to Veterans Administration Facilities and Department of Defense Healthcare Facilities
• Partnership with SunMED Medical Solutions, one of the premier medical equipment distributors and claim experts in the U.S., expands Endonovo’s distribution capabilities and expands ability of providers, facilities and patients to seek medical insurance reimbursement
• Holds 27 patents and numerous trademarks for several proprietary technologies and devices
• Agreement signed with national recognized hospital for use of SofPulse devices for wound healing and pain management
• Nationwide network of independent sales representatives and distributors

Endonovo Therapeutics Inc. (OTCQB: ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse Electroceutical Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.

Because SofPulse lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• INmune Bio is a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease
• Drug candidates INKmune and INB03 may be used to treat cancer; XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease
• The company was awarded a $1 million “Part the Cloud” grant from the Alzheimer’s Association to advance XPro1595 research
• INmune recently entered a common stock purchase agreement for up to $20 million with Lincoln Park Capital

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pursuing several drug candidates that utilize a precision therapy approach to treat unsolved problems in medicine. Among the company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease (http://ibn.fm/uX3hO).

INmune Bio recently posted its Q1 2019 financial results in a shareholder update, which highlighted the achievement of becoming the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on the Nasdaq Capital Market (http://ibn.fm/NGhG0). Importantly, INmune Bio was recognized by the Alzheimer’s Association with a “Part the Cloud” award that included a $1 million grant to further research into XPro1595 and the potential hope that it may bring to millions of patients with Alzheimer’s disease.

“2019 has marked a transformative period for INmune Bio, as the first biotech of the year to close its IPO and list on the Nasdaq,” RJ Tesi, M.D, INmune Bio’s chief executive officer, stated in a news release. “We are focused on advancing our clinical programs for the foreseeable future.”

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer’s disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer’s. A phase I clinical trial in patients with Alzheimer’s disease, supported by the Alzheimer’s Association grant, is expected to be initiated in the summer of 2019.

Upcoming catalysts for INmune Bio include advancements in several clinical trials featuring INB03 and INKmune – both of which are focused on “taking the brakes off” the body’s innate immune system to become a powerful weapon in the fight against cancer. INB03 is a checkpoint inhibitor that targets cells resistant to immunotherapy to instead become therapeutically effective; INKmune primes a patient’s own natural killer cells to move from a resting state to an active state to attack and eliminate residual disease (lingering cancer cells) after cancer therapy.

A recently published Zacks Small-Cap Research report values INmune Bio at $19 a share. David Bautz, PhD, who wrote the report, said that Zacks (http://ibn.fm/f2ejk) is “excited by the early clinical data INmune has compiled thus far and believe that the innate immune system is a currently untapped resource for extending the lives of cancer patients.”

INmune Bio also announced a common stock purchase agreement with Lincoln Park Capital Fund LLC, a Chicago-based institutional investor, for up to $20 million (subject to the terms of the agreements with Lincoln Park), which includes an initial investment of $300,000 (http://ibn.fm/3Zu9H). The investment is in addition to an earlier investment made by Lincoln Park during INmune Bio’s first round of funding in 2017, when the company was private.

“This financing agreement provides flexibility to opportunistically access capital at our option under favorable terms to advance our innate immune therapies in cancer and Alzheimer’s disease,” added David Moss, CFO of INmune Bio, noting that the funds will specifically help advance the company’s drug development pipeline into phase II clinical trials.

In addition, there was an insider-led round of investment totaling approximately $4.6 million, including investments by the company’s CEO and CFO.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB